In female C57BL/6JRj mice, Adooq-sourced doxazosin mesylate produced task-dependent changes in continuous-performance testing. Discriminability improved at 10.00 mg/kg in the variable stimulus duration schedule but did not improve significantly in the variable intertrial interval schedule. Reduced responding coincided with slower reward collection, and a separate locomotor assay showed reduced activity at 3.00 and 10.00 mg/kg. Motor suppression therefore limits interpretation of the behavioral effects. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Doxazosin mesylate in the mouse rCPT vSD schedule
Animal study · Female C57BL/6JRj mice; separate vSD cohort; n=36 reported for DOX in Figure 3 and Tables 2–4 [1]
In the variable stimulus duration schedule, 10.00 mg/kg increased discriminability and accuracy but reduced hit rate; 3.00 and 10.00 mg/kg reduced premature responding. Reward collection was slowed, limiting interpretation as a selective attention effect.
Conditions shared by the study groups
- Route
- Subcutaneous
- Frequency
- Individual test sessions twice weekly, with at least three days between tests
- Treatment course
- Counterbalanced Latin square with three doses and an internal vehicle session, flanked by vehicle reference sessions
- Vehicle
- 5% D-glucose and 5% hydroxypropyl-beta-cyclodextrin
- DOX dose series versus within-subject vehicle
- Model: Female C57BL/6JRj mice in the vSD schedule
- Reported limits: Methods overview says cohorts of 35 and 36; DOX figure/table captions specify 36 per schedule. Exact reconciliation is not given. No lot or SKU specified.
Methods and source locations
Compound reported in the paper: Doxazosin mesylate; Compound label in the paper: DOX
Reported mouse effects of Adooq-sourced doxazosin mesylate under these task conditions; no inference of human cognitive efficacy.
Materials and methods; rCPT analysis; Pharmacological interventions; Results: Variable stimulus duration schedule, Doxazosin; Table 3; Table 4; Figure 3 caption
Change in discriminability d′ at 10.00 mg/kg versus vehicle: Repeated-measures mixed model, post hoc fixed-effect estimate ± SE; d′ not logit-transformed. — Table 3, Discriminability d′, DOX High row; Methods rCPT data analysis
Hit rate, accuracy and premature responding versus vehicle: Repeated-measures mixed model of logit-transformed rate/percentage outcomes. — Results vSD Doxazosin; Table 3 relevant DOX rows
Reward collection latency versus vehicle: Latency analysis versus vehicle; reward latency log-transformed for analysis. — Table 4 vSD DOX Collection row; vSD Doxazosin latency results
DOX dose series versus within-subject vehicle · Materials and methods; rCPT training and testing; Pharmacological interventions; Results: Variable stimulus duration schedule, Doxazosin; Table 3; Table 4; Figure 3 caption
Doxazosin mesylate in the mouse rCPT vITI schedule
Animal study · Female C57BL/6JRj mice; separate vITI cohort; n=36 reported for DOX in Figure 3 and Tables 2–4 [1]
In the variable intertrial interval schedule, 10.00 mg/kg reduced both hit and false-alarm rates, without a significant discriminability improvement. First touches during intertrial intervals fell, but this occurred with slower reward collection and the separately demonstrated motor-depressant effect.
Conditions shared by the study groups
- Route
- Subcutaneous
- Frequency
- Individual test sessions twice weekly, with at least three days between tests
- Treatment course
- Counterbalanced Latin square with three doses and an internal vehicle session, flanked by vehicle reference sessions
- Vehicle
- 5% D-glucose and 5% hydroxypropyl-beta-cyclodextrin
- DOX dose series versus within-subject vehicle
- Model: Female C57BL/6JRj mice in the vITI schedule
- Reported limits: Methods overview says cohorts of 35 and 36; DOX figure/table captions specify 36 per schedule. Exact reconciliation is not given. No lot or SKU specified.
Methods and source locations
Compound reported in the paper: Doxazosin mesylate; Compound label in the paper: DOX
Reported mouse effects of Adooq-sourced doxazosin mesylate under these task conditions; no inference of human cognitive efficacy.
Materials and methods; rCPT analysis; Pharmacological interventions; Results: Variable intertrial interval schedule, Doxazosin; Table 2; Table 4; Figure 3 caption
Change in discriminability d′ at 10.00 mg/kg versus vehicle: Repeated-measures mixed model, post hoc fixed-effect estimate ± SE; d′ not logit-transformed. — Table 2, Discriminability d′, DOX High row
Hit rate, false-alarm rate, accuracy and first touches versus vehicle: Repeated-measures mixed model of logit-transformed outcomes. — Results vITI Doxazosin; Table 2 relevant DOX rows
Reward collection latency versus vehicle: Latency analysis versus vehicle; reward latency log-transformed for analysis. — Table 4 vITI DOX Collection row; vITI Doxazosin latency results
DOX dose series versus within-subject vehicle · Materials and methods; rCPT training and testing; Pharmacological interventions; Results: Variable intertrial interval schedule, Doxazosin; Table 2; Table 4; Figure 3 caption
Locomotor control after doxazosin mesylate in mice
Animal study · Female C57BL/6JRj mice pooled from the rCPT cohorts; n=9–10 per dose in Figure 6 caption [1]
Doxazosin reduced distance travelled at 3.00 and 10.00 mg/kg. The 1.00 mg/kg reduction was a trend. These findings limit attribution of reduced rCPT responding to impulsivity alone.
Conditions shared by the study groups
- Route
- Subcutaneous
- Frequency
- Each mouse tested twice, at least seven days apart, with different drugs and balanced treatments
- Treatment course
- Locomotor assessment following the rCPT experiments
- Vehicle
- 5% D-glucose and 5% hydroxypropyl-beta-cyclodextrin
- DOX locomotor dose series
- Model: Pooled female C57BL/6JRj rCPT mice; n=9–10 per dose
- Reported limits: No Adooq lot or SKU. This is a follow-up in pooled previously tested animals, not independent replication of the rCPT cohorts.
Methods and source locations
Compound reported in the paper: Doxazosin mesylate; Compound label in the paper: DOX
Mouse locomotor effect under the reported conditions, not a general sedative potency estimate.
Locomotor assay setup and analysis; Pharmacological interventions; Locomotor activity results; Figure 6
Total distance travelled versus vehicle: One-way ANOVA of log-transformed distance, Dunnett comparisons to vehicle; figure shows untransformed mean ± SEM. — Locomotor activity results; Figure 6 and caption
DOX locomotor dose series · Locomotor assay setup and analysis; Pharmacological interventions; Locomotor activity results; Figure 6